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SUMMARY To evaluate the neural regulation of postprandial somatostatin release we studied the
effect of blockade of (a) alpha-adrenergic and beta-adrenergic and (b) cholinergic receptors on
the plasma somatostatin, gastrin and insulin responses to a standard meal in two groups of five
fasting healthy male volunteers. Thymoxamine (0.1 mg/kg iv over two minutes then 10 mg/hour
for two hours) and propranolol (0.15 mg/kg iv over two minutes, then 0-75 mg/kg/hour for two
hours) were started just before eating while atropine (0.04 mg/kg/im) was given at 15 minutes on
completion of the meal. There was a prompt and sustained rise in plasma somatostatin after a
control meal in all experiments. This rise was arrested by atropine but not altered by either
thymoxamine or propranolol. The plasma gastrin response to a meal was moderately enhanced
by thymoxamine and markedly enhanced by atropine. Postprandial insulin release was not
affected by alpha- or beta-adrenergic blockade but was abolished by atropine. The effect of
atropine on the postprandial plasma somatostatin rise might have been mediated through
reduction in gastric acidity or delay in gastric emptying. Hence we gave five fasting male
volunteers an intraduodenal infusion of fat emulsion (25 calories in 30 minutes) on two occasions
both alone and after atropine. Plasma somatostatin rose during the fat infusion alone and this rise
was abolished by atropine. These data suggest that (a) cholinergic but not adrenergic mechanisms
are important modulators of plasma somatostatin release after orally ingested and
intraduodenally infused nutrients (b) atropine abolishes plasma somatostatin release
independently of its effects on gastric acidity and motility and (c) are consistent with the
hypothesis that atropine potentiates postprandial gastrin release through reduction of
somatostatin mediated inhibition.
Plasma somatostatin levels rise after a mixed meal in
man.1 Although the site of origin of postprandial
plasma somatostatin in man is uncertain, the
stomach, pancreas, and upper small gut are the most
likely sources. The neural mechanisms which
control postprandial release of somatostatin in man
are unknown. There is strong evidence, however, of
adrenergic and cholinergic modulation of basal and
stimulated release of somatostatin both in vitro and
in vivo. Samols and Weir report that somatostatin
release from isolated perfused canine pancreas was
stimulated by beta-adrenergic agonists and inhibited
by alpha-adrenergic agonists.2 Similarly, beta-
adrenergically mediated stimulation of the
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somatostatin release has been postulated in the
isolated rat stomach.3 Boden et al found that
beta-adrenergic agonists raised portal and arterial
plasma somatostatin in the intact dog, while alpha-
adrenerfic agonists suppressed somatostatin
release. Acetylcholine stimulates gastric and
pancreatic somatostatin release in vivo in the dog.5
Atropine reduces the gastric and pancreatic
somatostatin response to the gastric phase of a meal
in dogs.6
The present study was designed to investigate
autonomic control of release of plasma somatostatin
by food in man. The study comprised three parts. In
part 1 we studied the effect of alpha-adrenergic
blockade and beta-adrenergic blockade separately
on postprandial release of plasma somatostatin. In
part 2 we studied the effect of cholinergic blockade
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on postprandial plasma somatostatin, and as we will
describe, the postprandial rise was arrested.
Because this alteration might have been mediated
by reduction in gastric acidity, or delay in gastric
emptying, in part 3 we proceeded to study the effect
of a prior bolus of atropine on the plasma
somatostatin response to an intraduodenal infusion
of fat - a potent stimulus of plasma somatostatin
release in man7 which is unlikely to be affected by
changes in gastric acidity or motility.
Methods
SUBJECTS
Fifteen male volunteers, mean age 23 years (range
22-29 years), were within 10% of their ideal body
weight and taking no medication. None had a
history of endocrine, gastrointestinal, or renal
disease.' Alpha- and beta-adrenergic blockade: five
subjects received on three separate occasions a
standard breakfast (67 g carbohydrate, 17 g protein,
20 g fat, 560 calories, eaten over 15 minutes) plus a
continuous intravenous infusion of either (a) normal
saline, (b) thymoxamine 0-1 mg/kg for two minutes,
then 10 mg/h for two hours, or (c) propranolol 0-15
mg/kg for two minutes, then 0 75 mg/kg/h for two
hours, each starting just before eating.2 Cholinergic
blockade: five subjects were each given a standard
breakfast eaten over 15 minutes on two occasions
followed by an intramuscular bolus injection at 15
minutes of either saline or atropine (0-04 mg/kg).
On a third occasion, each subject received
intramuscular atropine alone.3 On two occasions a
further five subjects were intubated with a fine bore
flexible oroduodenal tube with its tip positioned in
the second part of the duodenum with radiographic
control and given a continuous infusion of fat
emulsion, for 30 minutes (12.5 ml 20% Intralipid,
KabiVitrum) made up to 125 ml pH 6 containing 25
calories. On one occasion an intramuscular injection
of atopine (0.04 mg/kg) was given prior to starting
the intraduodenal infusion. All experiments were
started at 8.30 am after an overnight fast. The
procedures were separated by at least one week and
carried out in random order. Blood for hormone
assay was taken through an indwelling needle.
Samples for hormone estimation were taken into
lithium heparin tubes containing 10 000 KIU
aprotonin, centrifuged at 4°C and separated. The
plasma was frozen immediately and stored at -20°C
until assay. These studies were approved by the
district ethical committee of Saint Bartholomew's
Hospital. All subjects gave fully informed consent.
method (Technicon). Plasma somatostatin, 8 insulin9
and gastrinl' were measured by radioimmunoassay
as previously described. All samples from each
individual subject were included in the same assay.
Somatostatin was extracted using Vycor glass; 1125
Tyrosine-somatostatin (4 pg/tube) was used as a
tracer, together with a highly specific rabbit anti-
somatostatin anti-serum (1 in 150 000) which gives a
sensitivity of 10 pg/ml plasma. The basal
somatostatin levels recorded in part 3 differed from
those in parts 1 and 2. This was due to a newly
prepared somatostatin standard solution which gave
higher numerical values.
STATISTICS
Results are expressed as mean±1 SEM. The





There were no consistent changes in pulse rate or
blood pressure during or after an infusion of
thymoxamine. The pulse rate fell in all subjects with
the infusion of propranolol from a mean basal rate
of 70±3 beats per minute to a nadir of 56±3 beats
per minute. (p<0.01).
Responses to a meal
Plasma glucose rose postprandially in all three
experiments to respective peak values of 6.4±0-6
mU/l (saline) 6-8±0-5 mU/l (thymoxamine) and
6 40±0-3 mU/l (propranolol). There were no
significant differences at any time point.
Somatostatin (Fig. 1)
The basal plasma somatostatin concentrations were
similar for each of the three experiments, the
combined mean being 18±1 pg/ml. There was a
prompt and sustained rise in plasma somatostatin
after the meal on each occasion to peaks of 48±9
pg/ml (saline) (p<0-02 compared with basal); 57± 10
pg/ml (thymoxamine) (p<002 compared with
basal) and 54±10 pg/ml (propranolol) (p<0.01
compared with basal). In the thymoxamine
experiment the postprandial plasma somatostatin
level significantly exceeded the saline control value
at 150 minutes only, 57±10 pg/ml compared with
43±10 pg/ml (p<0-02). Propranolol caused no
significant differences from the control responses at
any time point.
ASSAYS - Gastrin
Blood glucose was measured by the neocuproine There was a prompt and sustained rise in plasma
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Fig. 1 Plasma somatostatin, plasma gastrin andplasma
insulin in five subjects given a meal plus an intravenous
infusion ofsaline (0); a meal plus intravenous
thymoxamine (a); a meal plus intravenous propranolol
(A). Vertical bars are 1 SEM.
gastrin from a fasting level of 22±4 pg/ml to peaks at
15 minutes of 48±10 pg/ml (saline) (p<005
compared with basal), 64±17 pg/ml (thymoxamine)
(p<0O05 compared with basal) and 55±11 pg/ml
(propranolol) (p<0-02 compared with basal).
Plasma gastrin concentrations during the
thymoxamine experiment significantly exceeded
those in the control experiment at 45 minutes
(p<0-05) and 180 and 240 minutes (both p<0.02).
The plasma gastrin responses to a meal plus
propranolol significantly exceeded the control
values at 15 minutes (p<002) but were significantly
less than the control at 150 minutes (p<002).
Insulin
Plasma insulin concentrations rose to peak values of
72±21 mU/l (saline), 70±20 mU/l (thymoxamine)
and 77±18 mU/l (propranolol), respectively, each at
45 minutes and p<005 compared with basal. There
were no significant differences between the plasma
insulin levels in the control experiment and those




All subjects experienced dry mouth and tachycardia
after atropine. The pulse rate rose from a basal rate
of 70±3 beats per minute to a peak of a 107±3 beats
per minute within 45 minutes of administration of
atropine (p<001).
Responses to a meal (Fig 2)
Somatostatin
The fasting plasma somatostatin concentrations
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Fig. 2 Plasma somatostatin, plasma gastrin and
plasma insulin infive subjects given a meal plus saline
intramuscularly (0), a mealplus atropine
intramuscularly (A) and atropine intramuscularly alone
(-). Vertical bars are 1 SEM.
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were similar in all three subjects, combined mean
being 12±1 pg/ml. There was a prompt and
sustained rise in postprandial plasma somatostatin in
the control experiment to a peak of 27±4 pg/ml at 60
minutes (p<002 compared with basal). Atropine
arrested the expected rise in plasma somatostatin
when given 15 minutes after starting the meal. The
reduction in plasma somatostatin reached
significance at 60 minutes (p<0.01) 90 minutes
(p<002), 120 minutes and 150 minutes (each
p<005). After atropine alone the plasma
somatostatin levels fell to the limits of detection of
the assay.
Gastrin
There was a prompt and sustained rise in
postprandial plasma gastrin concentrations during
the control experiment to a peak at 30 minutes of
35±9 pg/ml (p<0.02 compared with basal) with the
levels returning to baseline by 240 minutes. When
the meal was followed by atropine, both the peak
and duration of the plasma gastrin response was
greater than in the saline control experiment, peak
54±12 pg/ml at 180 minutes (p<0.02 compared with
basal). The increase in the plasma gastrin response
to a meal plus atropine compared with the control
meal reached significance at 30 minutes (p<0.05),
45 minutes (p<0.01), 60 minutes (p<0.05), and at
all time points from 120 minutes to the end of the
experiment. There was no change in plasma gastrin
concentrations after atropine alone.
Insulin
Plasma insulin rose to a sustained peak of 57±13
mU/l at 30 minutes (p<005 compared with basal).
This postprandial rise was abolished by atropine and
the differences reached significance at 30, 45, and 60
minutes (p<0.02) and 90 minutes (p<0.05). Plasma
insulin levels did not change after atropine alone.
Intraduodenal infusion offat (Fig. 3)
Somatostatin
The basal somatostatin concentrations were similar
in both experiments, the mean level being 50±6
pg/ml. During the infusion of fat alone plasma
somatostatin levels rose promptly to a peak of
112±22 pg/ml at 30 minutes (p<002 compared with
basal), and rapidly returned to basal levels after the
completion of the infusion of fat. Before
administration of atropine abolished this response
and the differences between the atropine and
control experiment reached significance at 30
minutes (p<005). Plasma gastrin did not change
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Fig. 3 Plasma somatostatin infive subjects given an
intraduodenal infusion offat emulsion (12 5 ml 20%
Intralipid) both without (S) and with (A) atropine
intramuscularly. Vertical bars are 1 SEM.
Discussion
This study has shown in man that cholinergic
mechanisms are important in mediating post-
prandial plasma somatostatin release, but failed to
demonstrate such a role for adrenergic mechanisms.
There is no doubt that the doses of propranolol and
atropine were pharmacological, as marked and
consistent changes in pulse rate occurred. Although
objective evidence of alpha-adrenergic blockade
during infusion of thymoxamine was not available,
the dose used was 1 x 102 times greater than that
reported to attenuate the peripheral vasocon-
strictive effect of noradrenaline in normal
subjects.1" There are a number of possible
explanations for the failure to show a clear
involvement of either alpha- or beta-adrenergically
mediated control of postprandial plasma
somatostatin release, as has been suggested from
animal studies. 2-4 These include differences
between in vitro and in vivo models, species
variation in responses and differing specificities of
antibodies used in the assay of somatostatin. It is of
interest that Epstein and Berelowitz failed to alter
plasma somatostatin concentrations in man with
infusion of isoprenaline or dopamine, while
propranolol caused a slight decline in unstimulated
plasma somatostatin. 12 A further possible factor
may be the selectivity of thymoxamine for alpha-l-
adrenoceptors. 13 In the isolated perfused canine
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pancreas, however, somatostatin release is reduced
by phenoxybenzamine which, like thymoxamine,
also shows alpha-l-adrenoceptor selectivity.2
The action of atropine on postprandial circulating
somatostatin in the present study may be mediated
through direct cholinergic blockade. Alternatively,
it may be the indirect result of some other effect of
cholinergic blockade, such as reduction -in gastric
acid output or delay in gastric emptying. As atropine
also abolished the plasma somatostatin response to
an intradodenal infusion of fat, however, we suggest
that its action in reducing the plasma somatostatin
response to a luminal nutrient stimulus appears to
be independent of its effects on gastric acidity or
emptying, and is likely to be a direct result of
cholinergic blockade. This contention is consistent
with our data on the effect of intragastric and
intraduodenal infusions of dilute hydrochloric acid
on circulating somatostatin in man in which
somatostatin concentrations were unchanged by
intragastric acid infusions and rose moderatley only
when grossly supraphysiological doses of acid were
given intraduodenally.14 Thus acid per se is not a
major stimulus of plasma somatostatin while the
vagus nerve appears to directly mediate the release
of plasma somatostatin after oral or intraduodenal
nutrients. Similarly, vagotomy'5 and autonomic
neuropathy'6 prevent the plasma somatostatin rise
after insulin-induced hypoglycaemia.
Tfie regulation of gastrin release in man is
complex and there is evidence to suggest both beta-
and alpha-adrenergic modulation. Exogenous
adrenaline stimulates gastrin release and this is
inhibited by beta-blockade in man.17 Propranalol
reduces the plasma gastrin response to gastric
distension in man. 18 Phentolamine, when given with
atropine, but not when given alone increases the
plasma gastrin response to this stimulus.18 The
moderate increase in postprandial plasma gastrin
during an infusion of thymoxamine but not
propranolol in the present study suggests the
participation of alpha-adrenergic mechanisms in
postprandial gastrin release, but does not elucidate
further the contribution if any of beta-adrenergic
mechanisms.
Atropine augmented the plasma gastrin response
to food confirming the work of other investi-
gators.19 20 Atropine has been reported to enhance
gastrin release after gastric distension21 and sham
feeding.22 The mechanism of cholinergically
mediated inhibition of gastrin release in man is
unknown, but Feldman et al have questioned
whether somatostatin could be an intermediate in
this pathway.22 In the isolated rat stomach infusion
of anti-somatostatin antiserum stimulates gastrin
release and this may be a cholinergic
phenomenon.23 Hence Saffouri et al postulate that
somatostatin exerts a continuous restraint on gastrin
release.23 Our data are consistent with the
hypothesis that atropine augments the postprandial
release of gastrin by reduction in somatostatin
mediated inhibition.
The failure of thymoxamine to alter the
postprandial release of plasma insulin differs from
previous reports in man of enhancement by
phentolamine of insulin release following
intravenous or intraduodenal glucose,24 25 or
intravenous arginine.26 As phentolamine is an
antagonist at both alpha-1 and alpha-2-
adrenoceptors, receptor selectivity may account for
this discrepancy. Indeed Nakadate et al have
suggested that in mice alpha-2 rather than alpha-i-
adrenoceptors influence plasma insulin levels.27
Propranolol has been reported to reduce the plasma
insulin response to an oral or intraduodenal glucose
load in man.24 25 It is not clear why beta-adrenergic
blockade had no effect on plasma insulin responses
to a meal in the present study. The abolition by
atropine of the postprandial rise in plasma insulin is
in keeping with previous reports of inhibition by
atropine of insulin secretion after an oral glucose
load in man.28
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